dc.identifier.citation |
Bae, SC, Koh, HK, Chang, D, Kim, M, Park, J, et al, 2000: Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 10, 6:405-9. Bombardier, C, Gladman, DD, Urowitz, MB, Caron, D, Chang, CH, 1992: Derivation of the SLEDAI: A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 35:630-40. Bruns, A, Blass, S, Hausdorf, G, Burmester, GR, Hiepe, F, 2000: Nucleosomes are major T and B cell autoantigens in the systemic lupus erythematosus. Arthritis Rheumat. 43: 2307-15. Casali, P, Schettino, EW, 1996: Structure and function of natural antibodies. Curr. Top. Microbiol. Immunol. 210:167-79 Ceppellini, P, Polli, E, Celada, F, 1957: A DNA-reacting factor in serum of a patient with lupus erythematous diffusus. Proceed. Soc. Exp. Biol. Med. 96:572-4. Chu, P, Pendry, K, Blecher, TE, 1988: Detection of lupus anticoagulant in patients’ attending an anticoagulation clinic. Brit. Med. J. 297: 1449-53 Cozzani, E, Drosera, M, Gasparini, G, Parodi, A, 2014: The serology of lupus erythematosus: Correlation between immunopathological features and clinical aspects. Autoimm. Dis. 4:1-13. Egner, W, 2000: The use of laboratory tests in diagnosis of SLE. J. Clin. Pathol. 53, 6:424-32 Elkon, K, Casali, P, 2008: Nature and functions of autoantibodies. Nat. Clin. Pract. Rheumatol. 4, 9: 491-8. Grygiel-Górniak, B, Rogacka, N, Puszczewi cz, M, 2018: Antinuclear antibodies in healthy people and non-rheumatic diseases - diagnostic and clinical implications. Reumatol. 56, 4:243-8. Hamdy, S, Gamal, T. Khalil, AK, Ibrahim, NI, 2010: Pattern of systemic lupus erythematosus in Egyptian patients: the impact of disease activity on the quality of life. Pan Afr. Med. J. 6:14-20. Mechanisms of autoantibody production in systemic lupus erythematosus. Front Immunol. 6:22-8. Hargraves, M, Richmond, H, Morton, R, 1948: Presentation of two bone marrow components, the tart cell and the LE cell. Mayo Clin. Proceed. 21:25-8. Hochberg, MC, 1997: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40:1725 Kurien, BT, Scofield, RH, 2006: Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand. J. Immunol. 64: 227-35. Müller, MM, Muir, TW, 2014: Histones: At the crossroads of peptide and protein chemistry. Chem. Rev. 115, 6: 2296-349. Nagai, T, Arinuma, Y, Yanagida, T, Yamamoto, K, Hirohata, S, 2005: Anti-ribosomal P protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral blood monocytes. Arthritis Rheum. 52, 3:847-55. Perrin, LH, Lambert, PH, Nydegger, UE, Miescher, PA, 1973: Quantitation of C3PA (properdin factor B) and other complement components in diseases associated with a low C3 level. N. Engl. J. Med. 2:16-27. Sherer, Y, Gorstein, A, Fritzler, MJ, Shoenfeld, Y, 2004: Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 34: 501-37. Stoll, TS, Stucki, G, Malik, J, 1996: Further validation of the BILAG disease activity index in patients with SLE. Ann. Rheum. Dis. 55, 10:756-60. Tan, EM, Kunkel, HG, 1966: Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J. Immunol. 96:464-71. van der Vlag, J, Berden, JHM, 2011: Lupus nephritis: Role of anti-nucleosome antibodies. Semin. Nephrol. 31:376-89. Walport, MJ, 2002: Complement and systemic lupus erythematosus. Arthritis Res. 4: S279-93. Walravens, M, 1987: Systemic diseases and the detection of nuclear and anticytoplasmic antibodies: A historical review. Clin. Rheumatol. 6:9-17. |
en_US |